Patent · US Active

Single chain CD40L fusion polypeptides

US9340599B2 · kind B2 · utility

15Cited by

1References

16Claims

0Family size

Assignee

APOGENIX AG · DE

Inventors

Oliver Hill · Neckarsteinach, DE
Christian Gieffers · Dossenheim, DE
Meinolf Thiemann · Schriesheim, DE

Key dates

Filing date	Dec 2, 2014
Grant date	May 17, 2016
Priority date	—
Expiry date	Dec 2, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.